FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 60 filers reported holding FATE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $467,000 | -24.3% | 20,820 | +100.0% | 0.05% | -37.8% |
Q3 2021 | $617,000 | +14.9% | 10,410 | +68.2% | 0.07% | +37.0% |
Q2 2021 | $537,000 | -17.9% | 6,190 | -21.9% | 0.05% | -27.0% |
Q1 2021 | $654,000 | +116.6% | 7,927 | -9.9% | 0.07% | +64.4% |
Q2 2020 | $302,000 | -42.9% | 8,798 | -67.4% | 0.04% | -47.1% |
Q4 2019 | $529,000 | +192.3% | 27,025 | +161.9% | 0.08% | +183.3% |
Q1 2019 | $181,000 | +82.8% | 10,317 | -52.4% | 0.03% | +30.4% |
Q1 2017 | $99,000 | – | 21,654 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |